omaveloxolone , Nuclear factor erythroid 2-related factor 2 activator, CAS No.O612486, Nuclear factor erythroid 2-related factor 2 activator

Item Number
O612486
Grouped product items
SKUSizeAvailabilityPrice Qty
O612486-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
O612486-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,001.90

Basic Description

SynonymsOmaveloxolone | 1474034-05-3 | RTA-408 | RTA 408 | Nrf1-activator-1 | SKYCLARYS | Omaveloxolone [INN] | UNII-G69Z98951Q | G69Z98951Q | Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro- | N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9
Specifications & PurityMoligand™
GradeMoligand™
Action TypeACTIVATOR
Mechanism of actionNuclear factor erythroid 2-related factor 2 activator

Associated Targets(Human)

NFE2L2 Tchem Nuclear factor erythroid 2-related factor 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HT-29 (80576 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

L929 (3802 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
INCHI InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
InChi Key RJCWBNBKOKFWNY-IDPLTSGASA-N
Canonical SMILES N#CC1=C[C@@]2(C)[C@H](C(C1=O)(C)C)CC[C@@]1(C2=CC(=O)[C@H]2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(C)CC1)NC(=O)C(F)(F)C)C
Isomeric SMILES C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
PubChem CID 71811910

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW.  (2014)  Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin..  Arch Dermatol Res,  306  (5): (447-54).  [PMID:24362512]
2. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW.  (2014)  Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis..  Radiat Res,  181  (5): (512-20).  [PMID:24720753]
3. Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto M, Ward KW.  (2019)  Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates..  Drug Des Devel Ther,  13  (3): (1259-1270).  [PMID:31118567]
4. Ghanekar SD, Miller WW, Meyer CJ, Fenelon KJ, Lacdao A, Zesiewicz TA.  (2019)  Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone..  Degener Neurol Neuromuscul Dis,  (3): (103-107).  [PMID:31686946]
5. Profeta V, McIntyre K, Wells M, Park C, Lynch DR.  (2023)  Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia..  Expert Opin Investig Drugs,  32  (1): (5-16).  [PMID:36708320]
6. Li W, Kong AN.  (2009)  Molecular mechanisms of Nrf2-mediated antioxidant response..  Mol Carcinog,  48  (2): (91-104).  [PMID:18618599]

Solution Calculators